Federal Register - February 4, 2021
Versión en texto ¿Qué es?Dateas es un sitio independiente no afiliado a entidades gubernamentales. La fuente de los documentos PDF aquí publicados es la entidad gubernamental indicada en cada uno de ellos. Las versiones en texto son transcripciones no oficiales que realizamos para facilitar el acceso y la búsqueda de información, pero pueden contener errores o no estar completas.
Fuente: Federal Register
8214
Federal Register / Vol. 86, No. 22 / Thursday, February 4, 2021 / Notices
the host, and provides protective efficacy after a single dose.
This technology is available for licensing, as a biological material, for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
Potential Commercial Applications Single dose vaccine against COVID
19
Competitive Advantages Utilizes the established and well characterized VSVEBOV vector Expresses high antigen titers within host cells Single dose protective efficacy against COVID19
Inexpensive and replicable Development Stage Prototype In vivo/In vitro Inventors: Andrea Marzi NIAID, Wakako Asada NIAID.
Licensing Contact: To license this technology, please contact Jeffrey Thruston at 3015945179 or jeffrey.thruston@nih.gov, and reference E23320170.
Dated: January 19, 2021.
Surekha Vathyam, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.
FR Doc. 202102294 Filed 2321; 8:45 am BILLING CODE 414001P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
jbell on DSKJLSW7X2PROD with NOTICES
National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious Diseases, Special Emphasis Panel; NIAID New Innovators Awards DP2 Clinical Trial Not Allowed.
VerDate Sep<11>2014
17:13 Feb 03, 2021
Jkt 253001
Date: March 23, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3F52, Rockville, MD 20892 Virtual Meeting.
Contact Person: Jennifer H. Meyers, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3F52, Rockville, MD
20852, 3017616602, jennifer.meyers@
nih.gov.
Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS
Dated: January 26, 2021.
Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy.
FR Doc. 202102276 Filed 2321; 8:45 am BILLING CODE 414001P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health National Library of Medicine; Notice of Closed Meetings Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Library of Medicine Special Emphasis Panel; K99 and COI.
Date: March 18, 2021.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Video Assisted Meeting.
Contact Person: Leonid V. Tsap, Ph.D., Scientific Review Officer, Extramural Programs, National Library of Medicine, NIH, 6705 Rockledge Drive, Suite 500, Bethesda, MD 208927968, 3018277077, tsapl@
mail.nih.gov.
Catalogue of Federal Domestic Assistance Program No. 93.879, Medical Library Assistance, National Institutes of Health, HHS
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Dated: January 26, 2021.
Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy.
FR Doc. 202102279 Filed 2321; 8:45 am BILLING CODE 414001P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Biobehavioral and Behavioral Processes Integrated Review Group; Human Complex Mental Function Study Section.
Date: February 2426, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 Virtual Meeting.
Contact Person: Karen Elizabeth Seymour, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD
20892, 2407622729, karen.seymour@
nih.gov.
Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Group; Acute Neural Injury and Epilepsy Study Section.
Date: February 2526, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
Virtual Meeting.
Contact Person: Paula Elyse Schauwecker, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5201, Bethesda, MD 20892, 3017608207, schauweckerpe@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis Panel; Brain Injury and Neurovascular Pathologies.
Date: February 26, 2021.
Time: 12:00 p.m. to 4:00 p.m.
E:FRFM04FEN1.SGM
04FEN1